How should safety be managed when new safety information emerges?

• A. Review only at the end of the trial.
• B. Review in a timely manner as information becomes available.
• C. Ignore until major adverse events occur.
• D. Review only if requested by regulator.

Answer: (B)

When new safety information emerges, it must be reviewed promptly as it becomes available. Ongoing safety monitoring relies on continuously assessing accumulating data and any signals of risk, so protective actions can be taken without delay. This approach keeps the risk-benefit balance current, allows risk mitigation measures to be put in place, and ensures investigators, ethics committees, and regulators are informed as required. Delaying review until the end, ignoring signals, or waiting for regulatory requests can put participants at unnecessary risk and undermine the study’s integrity. In practice, a new safety signal might trigger actions such as protocol amendments, changes to informed consent, more frequent safety reviews, temporary pauses in enrollment, or additional safety reporting, all aimed at safeguarding participants while the information is evaluated.